TY - JOUR T1 - The competing risk between in-hospital mortality and recovery: A pitfall in COVID-19 survival analysis research JF - medRxiv DO - 10.1101/2020.07.11.20151472 SP - 2020.07.11.20151472 AU - Abderrahim Oulhaj AU - Luai A. Ahmed AU - Juergen Prattes AU - Abubaker Suliman AU - Ahmed R. Alsuwaidi AU - Rami H. Al-Rifai AU - Harald Sourij AU - Ingrid Van Keilegom Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/15/2020.07.11.20151472.abstract N2 - Background A plethora of studies on COVID-19 investigating mortality and recovery have used the Cox Proportional Hazards (Cox PH) model without taking into account the presence of competing risks. We investigate, through extensive simulations, the bias in estimating the hazard ratio (HR) and the absolute risk reduction (ARR) of death when competing risks are ignored, and suggest an alternative method.Methods We simulated a fictive clinical trial on COVID-19 mimicking studies investigating interventions such as Hydroxychloroquine, Remdesivir, or convalescent plasma. The outcome is time from randomization until death. Six scenarios for the effect of treatment on death and recovery were considered. The HR and the 28-day ARR of death were estimated using the Cox PH and the Fine and Gray (FG) models. Estimates were then compared with the true values, and the magnitude of misestimation was quantified.Results The Cox PH model misestimated the true HR and the 28-day ARR of death in the majority of scenarios. The magnitude of misestimation increased when recovery was faster and/or chance of recovery was higher. In some scenarios, this model has shown harmful treatment effect when it was beneficial. Estimates obtained from FG model were all consistent and showed no misestimation or changes in direction.Conclusion There is a substantial risk of misleading results in COVID-19 research if recovery and death due to COVID-19 are not considered as competing risk events. We strongly recommend the use of a competing risk approach to re-analyze relevant published data that have used the Cox PH model.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAbderrahim Oulhaj and Luai A. Ahmed, are supported by a grant from Zayed Center for Health Sciences, United Arab Emirates University (31R239). Ingrid Van Keilegom gratefully acknowledges support from the European Research Council (2016-2021, Horizon 2020 / ERC grant agreement No. 694409). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable. This is a simulation study. No data on real human patients was used. The IRB is not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is a simulation study. No data on real patients was used. Upon justifiable request, the authors are happy to share the Data Generating Process (DGP) from which the simulations were carried out ER -